Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents
暂无分享,去创建一个
R. Chung | R. Thadhani | D. Steele | Allyson K. Bloom | Andrew L. Lundquist | A. Kim | M. Sise | N. Hashemi | M. Thiim | W. Williams | J. Gustafson | Jessica Wisocky | M. Lin | Ming V. Lin
[1] A. Fabbrizzi,et al. Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study , 2015, Hepatology.
[2] K. Reddy,et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. , 2015, Journal of hepatology.
[3] K. Reddy,et al. Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus , 2015, Hepatology.
[4] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[5] J. Stine,et al. Treatment of chronic hepatitis C complicated by mixed cryoglobulinemia with new protease inhibitor, sofosbuvir , 2014, Annals of the rheumatic diseases.
[6] S. Mauss,et al. Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir , 2014, Hepatology.
[7] Brad J. Wood,et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. , 2013, JAMA.
[8] O. Decaux,et al. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24 , 2013, Annals of the rheumatic diseases.
[9] M. Miccoli,et al. Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2 , 2013, Clinical Rheumatology.
[10] P. Messa,et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] F. Fabrizi. Hepatitis C Virus, Cryoglobulinemia, and Kidney: Novel Evidence , 2012, Scientifica.
[12] Zonghui Hu,et al. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. , 2012, Arthritis and rheumatism.
[13] J. Piette,et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. , 2010, Blood.
[14] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[15] C. Ferri,et al. Mixed cryoglobulinemia , 2008, Orphanet journal of rare diseases.
[16] S. Baldovino,et al. Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia , 2008, Clinical reviews in allergy & immunology.
[17] J. Piette,et al. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. , 2006, Arthritis and rheumatism.
[18] Y. Ngo,et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. , 2006, Clinical chemistry.
[19] L. Quartuccio,et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. , 2006, Rheumatology.
[20] Andrew H Talal,et al. Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. , 2005, Blood.
[21] J. Piette,et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] J. Hoofnagle,et al. Hepatitis C and renal disease: an update. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] G. Mazzucco,et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. , 2003, Kidney international.
[24] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[25] C. Alpers,et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection , 1993, Pediatric Nephrology.
[26] C. Alpers,et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[27] R. Chung,et al. A role for hepatitis C virus infection in type II cryoglobulinemia. , 1992, The New England journal of medicine.
[28] G. Borelli,et al. Hepatitis C Virus Infection in Patients with Essential Mixed Cryoglobulinemia , 1992, Annals of Internal Medicine.
[29] J. Clauvel,et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. , 1974, The American journal of medicine.
[30] O. Decaux,et al. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. , 2015, Journal of hepatology.